Agenus Inc. Logo
New Clinical Responses for AGEN1181 Presented at AACR
April 10, 2021 08:35 ET | Agenus Inc.
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically unresponsive to I-O agents ...
TCRR Logo.png
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
April 10, 2021 08:31 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
Arch Oncology Logo_RGB.jpg
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
April 10, 2021 08:31 ET | Arch Oncology
BRISBANE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today...
Hookipa Pharma Logo Square.png
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
April 10, 2021 08:31 ET | Hookipa Pharma Inc
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202Early data on HB-201 monotherapy show an...
VINCERX.png
Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
April 10, 2021 08:31 ET | Vincerx Pharma, Inc.
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies on track for 1H 2022 PALO ALTO, Calif., April 10, 2021 (GLOBE NEWSWIRE)...
jounce.png
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
April 10, 2021 08:31 ET | Jounce Therapeutics, Inc.
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature- - JTX-8064’s mechanism of...
advaxis-squarelogo-1498831554460.png
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
April 10, 2021 08:31 ET | Advaxis, Inc.
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade Assay enables determination of PD-1...
CRISPR_Logo.jpg
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
April 10, 2021 08:31 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Inivata_CMYK_Logo.jpg
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021
April 10, 2021 08:30 ET | Inivata
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021 Inivata’s RaDaR® MRD assay performed with exceptionally high sensitivity and...
NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
April 10, 2021 08:30 ET | NuCana plc
NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer...